Shanghai MicroPort MedBot Issues Positive Profit Alert: First-Ever Semi-Annual Profit Expected
Key Points for Investors
- First Semi-Annual Profit in Company History: Shanghai MicroPort MedBot (Group) Co., Ltd. has announced, based on preliminary unaudited consolidated management accounts for the six months ended 30 June 2026, that it expects to turn from a net loss to a net profit for the period. The anticipated net profit is between RMB 28 million and RMB 40 million, a significant improvement compared to a net loss of RMB 115 million for the same period in 2025.
- Revenue Growth: The Group achieved a year-on-year revenue increase of approximately 200% to 230%. This remarkable growth was driven by the Toumai Laparoscopic Surgical Robot, which saw robust sales expansion in both domestic and overseas markets. Notably, overseas revenues grew by more than 450% year-on-year. The growth is attributed to the product’s technical competitiveness, strong clinical performance, and effective use of MicroPort’s overseas sales channels.
- Gross Profit Margin Improvement: The company’s overall gross profit margin improved by more than 15 percentage points compared to the same period last year. This was driven by higher production scales diluting fixed costs, continuous optimization in production processes reducing direct labour and material costs, and a rapid increase in revenue from high-margin consumables.
- Expense Control: Operating expenses as a ratio to revenue dropped significantly, further enhancing operational efficiency. This was the result of ongoing efforts to optimize expense control and resource allocation.
- Upcoming Results Announcement: The company’s interim results for the Reporting Period are not yet finalized and will be published on or before 31 August 2026. The figures released in this alert are based on preliminary, unaudited numbers and may be subject to adjustments.
Potentially Price-Sensitive Information
- First Semi-Annual Profitability Milestone: This is the first time the company has achieved profitability in any half-year period, marking a significant milestone in its growth trajectory.
- Substantial Revenue and Margin Expansion: The dramatic increase in both revenue and gross profit margin strongly signals improved business fundamentals and potential for sustained profitability, which may positively impact the company’s valuation and share price.
- Strong International Growth: With overseas revenue growth of over 450%, the company is demonstrating successful international market penetration, an important factor for future growth prospects.
- Expense Ratio Reduction: Improved operational efficiency through better expense control is a clear sign of maturing business operations and should be viewed positively by investors.
- Results Are Preliminary: Investors should note that these figures are unaudited and subject to change upon finalization of the interim results.
Board Statement and Warning to Investors
The Board of Directors emphasizes that the data presented is based on preliminary internal assessments and unaudited accounts. Shareholders and potential investors are advised to interpret these results with caution and await the publication of the official interim results for the period ended 30 June 2026, which are expected on or before 31 August 2026.
Conclusion
The anticipated turnaround from a substantial net loss to a net profit, coupled with exponential revenue and international growth, marks a critical inflection point for Shanghai MicroPort MedBot. These developments are highly significant and may materially affect the company’s share price upon market reaction.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. All financial figures are based on unaudited preliminary results and may be subject to further adjustments. Investors should exercise caution and consult official announcements and financial statements before making any investment decisions.
上海微創機器人集團正面盈利預告：公司首度實現半年盈利
投資者重點
- 公司歷史性半年盈利： 根據2026年6月30日止六個月的初步未經審核合併管理賬目，上海微創機器人集團（股份代號：2252）預計將由虧轉盈，實現淨利潤約人民幣2,800萬至4,000萬元，對比2025年同期虧損1.15億元，為公司首次半年盈利。
- 收入大幅增長： 集團錄得同比收入增長約200%至230%。其中，圖邁腔鏡手術機器人於國內外市場銷售大增，海外收入更同比大增超過450%，受產品技術競爭力、臨床表現及微創醫療海外銷售資源協同推動。
- 毛利率顯著提升： 公司整體毛利率同比提升超15個百分點。因產能規模擴大攤薄固定成本，生產流程持續優化，直接人工及物料成本下降，高毛利耗材收入亦快速增長。
- 費用控制持續優化： 期內營運費用佔收入比顯著下降，進一步提升經營效率，體現公司資源配置持續優化成效。
- 業績公佈時間： 中期業績仍在編製中，最終業績將於2026年8月31日或之前公佈。現時所有數據為初步未經審核，有待最終確認。
或影響股價的重要事項
- 首度實現半年盈利： 公司首次錄得半年盈利，標誌業務發展重要里程碑，或對股價帶來積極影響。
- 收入及毛利率大升： 業績增長動能強勁，業務基本面持續改善，有利市場對公司估值提升。
- 海外市場爆發增長： 海外收入同比暴增超過450%，國際化進程成果明顯，有助未來增長前景。
- 費用率下降： 營運效率提升，顯示公司經營日趨成熟，為可持續盈利奠定基礎。
- 業績初步性質： 投資者需留意業績數據為未經審核初步資料，最終以正式公告為準。
董事會聲明及投資者提示
董事會強調，公告數據為初步內部評估及未經審核賬目，股東及潛在投資者應審慎解讀，並留意2026年6月底中期業績將於8月31日或之前正式發佈。
結語
由大幅虧損轉為盈利，加上收入及海外業務爆發性增長，為上海微創機器人集團發展進入新台階，屬極具市場敏感度及或影響股價的重大利好消息。
免責聲明
本文僅作資訊參考，並不構成任何投資建議。所有數據均為未經審核初步結果，或會作進一步調整。投資者應審慎行事，並以公司正式公告及財務報表為準。
